Inside the research

Johnson & Johnson

JNJ Research profile · latest available data

Price overview

$271.22

▲ +0.54 (+0.2%)

52w hi$278.43
52w lo$173.81
Vol4.09M
As of25 Sep 2026

The Verdict

Hold

Our score +0.23

Short+0.16
Medium+0.33
Long+0.17

computed 2026-09-27

Key fundamentals

Johnson & Johnson

Healthcare · Drug Manufacturers - General

Market cap$653.61B
Enterprise value$681.89B
Trailing P/E31.46x
Forward P/E22.34x
EV / EBITDA19.55x
P / S (ttm)6.67x
Profit margin21.5%
Return on equity25.7%
Revenue growth+6.6%
Earnings growth-0.9%
Debt / equity57.71

Layer Breakdown

LayerRawContribution
Fundamental+0.18
Sector+0.08
Technical+0.13
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

United States · www.jnj.com

Risk Metrics

Beta vs SPX-0.02
Corr SPX-0.02
Annual vol19.1%
Annual ret+26.9%
Sharpe1.41
Max DD-14.3%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$252.42
High / Low$285.00 / $155.00
Median$259.00
Analysts24
Strong Buy5
Buy9
Hold10
Sell0
Strong Sell1

Recent rating actions

2026-04-15Wells Fargo→ Overweight
2026-04-15Stifel→ Hold
2026-04-15Barclays→ Equal-Weight
2026-04-10Morgan Stanley→ Overweight
2026-03-30RBC Capital→ Outperform
2026-03-19Barclays→ Equal-Weight

Officers & Board

DirectorPaula Johnson since 2023
DirectorDarius Adamczyk since 2022
CEOJoaquin Duato since 2022
DirectorJoaquin Duato since 2022
DirectorNadja West since 2020
DirectorMark Weinberger since 2019
DirectorHubert Joly since 2019
DirectorMarillyn Hewson since 2019
DirectorJennifer Doudna since 2018
DirectorMary Beckerle since 2015
DirectorScott Davis since 2014
DirectorMark McClellan since 2013
DirectorAnne Mulcahy since 2009
FounderEdward Mead Johnson current
FounderJames Wood Johnson current

Material Events

DateEvent8-K
2026-08-04Officer / Director Change, Exhibitsread
2026-07-29Reg FD Disclosure, Exhibitsread
2026-07-28Reg FD Disclosure, Exhibitsread
2026-07-15Earnings Release, Exhibitsread
2026-04-28Shareholder Vote, Exhibitsread
2026-04-14Earnings Release, Other Material Event…read
2026-01-21Earnings Release, Exhibitsread
2025-10-14Earnings Release, Other Material Event…read
2025-09-09Officer / Director Changeread
2025-07-16Earnings Release, Exhibitsread
2025-06-10Officer / Director Changeread
2025-04-30Officer / Director Change, Shareholder Vote…read

Insider Trades

DateInsiderRoleActionSharesValue
2026-08-13Duato JoaquinCEO and Chairman of the BSell20.98K$5.50M
2026-08-13Duato JoaquinCEO and Chairman of the BSell102.31K$26.70M
2026-08-13Duato JoaquinCEO and Chairman of the BOption exercise123.29K$14.26M
2026-08-06Forminard ElizabethEVP, Chief Legal OfficerOption exercise9.34K$1.23M
2026-08-06Forminard ElizabethEVP, Chief Legal OfficerSell6.57K$1.68M
2026-08-06Forminard ElizabethEVP, Chief Legal OfficerSell9.34K$2.41M
2026-08-05Duato JoaquinCEO and Chairman of the BSell6.52K$1.69M
2026-08-05Duato JoaquinCEO and Chairman of the BSell41.96K$10.83M
2026-07-20Broadhurst VanessaEVP, Global Corp AffairsOption exercise11.13K$1.44M
2026-07-20Broadhurst VanessaEVP, Global Corp AffairsSell23.05K$5.79M

Flow & Concentration

Insider 180d net-$57.01M
Insider buys / sells0 / 8
Insider biasSellers
13F holders8
Top-5 share98.4%
HHI5,605 (concentrated)

Top Holders

HolderValueShares
State Street Corp$33.98B133.78M
Fidelity / FMR LLC$5.74B22.60M
Capital Research / Capital World$2.99B11.77M
Citadel Advisors$2.13B8.39M
AQR Capital Management$738.49M2.91M
Millennium Management$549.64M2.16M
Bridgewater Associates$169.94M669.13K
T. Rowe Price Group$5.84M23.00M

As of 2026-06-30

Connections

Subsidiarys: Johnson & Johnson Pharmaceutical Research and Development

Dividends

Yield (TTM)0.96%
$ / share (TTM)$2.60
5y CAGR+5.2%

Annual dividend per share

2021$4.19
2022$4.45
2023$4.70
2024$4.91
2025$5.14
2026$1.30

Federal Contracts

AmountAgencyDescription
$1.38MDepartment of Veterans AffairsDRY CHEMISTRY/IMMUNOCHEMISTRY SYSTEM
$1.36MDepartment of DefenseCHEMISTRY ANALYZER
$1.26MDepartment of Veterans AffairsCHEMISTRY
$982.69KDepartment of DefenseCHEMISTRY ANALYZER
$891.05KDepartment of Defense4569174801!2.7MM/3.5MM VA-LCP ANKLE
$868.52KDepartment of DefenseIMMUNOASSAY TESTING
$745.32KDepartment of Defense4569301060!2.7MM/3.5MM VA-LCP ELBOW
$633.80KDepartment of DefenseCOST PER REPORTABLE VITROS 5600

SEC Filings

DateFormDoc
2026-08-144view
2026-08-074view
2026-08-074view
2026-08-0613F-HRview
2026-08-048-Kview
2026-07-298-Kview
2026-07-288-Kview
2026-07-2310-Qview
2026-07-214view
2026-07-158-Kview
2026-06-2511-Kview
2026-06-2511-Kview
2026-06-124view
2026-06-114view
2026-06-114view

The Long Run

FY 2009–2025 · 17 years

LineLatestCAGRTrend
Revenue$94.19B+2.7%
Gross profit$63.94B+2.5%
Operating income$21.59B+6.8%
Net income$26.80B+19.1%
Cash from ops$22.79B+2.6%

Indices

S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$271.70$272.25$269.26$271.224.09M
Sep 24$269.52$275.23$269.01$270.686.32M
Sep 23$269.47$272.14$266.50$269.176.63M
Sep 22$267.51$270.10$265.04$269.195.68M
Sep 21$271.74$273.73$268.50$269.474.49M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →